


PHARMACEUTICAL 2018

Cocrystal Pharma Inc. Rank 23 of 342





PHARMACEUTICAL 2018



Cocrystal Pharma Inc. Rank 23 of 342

The relative strengths and weaknesses of Cocrystal Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cocrystal Pharma Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Cocrystal Pharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 263%, being 217% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	2,176
Cost of Goods Sold	0
Intangible Assets	65,195
Liabilities, Current	1,406
Liabilities, Non-Current	14,620
Other Assets	53,936
Other Compr. Net Income	0
Other Expenses	-6,880
Other Liabilities	0
Other Net Income	769
Other Revenues	0
Property and Equipment	119
Research and Development	5,822
Selling, General and Administrative Expense	2,440

Output Variable	Value in 1000 USD
Assets	121,426
Liabilities	16,026
Expenses	1,382
Revenues	0
Stockholders Equity	105,400
Net Income	-613
Comprehensive Net Income	-613
Economic Capital Ratio	263%

